Progression-free survival in the ICON8 trial - Authors' reply

Affiliations

¹ Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK. Electronic address: e.james@ucl.ac.uk.
² Department of Surgery and Cancer, Imperial College London, London, UK.
³ Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
⁴ Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.

Comment

Elizabeth C James et al. Lancet. 2020.

. 2020 Sep 12;396(10253):757.

doi: 10.1016/S0140-6736(20)31177-6.

¹ Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK. Electronic address: e.james@ucl.ac.uk.
² Department of Surgery and Cancer, Imperial College London, London, UK.
³ Medical Research Council Clinical Trials Unit at University College London, Institute of Clinical Trials & Methodology, University College London, London WC1V 6LJ, UK.
⁴ Department of Medical Oncology, The Christie National Health Service Foundation Trust and University of Manchester, Manchester, UK.

No abstract available

Comment on

Progression-free survival in the ICON8 trial.
Balieiro Anastacio da Costa AA, Baiocchi G, Guimarães APG. Balieiro Anastacio da Costa AA, et al. Lancet. 2020 Sep 12;396(10253):756-757. doi: 10.1016/S0140-6736(20)31176-4. Lancet. 2020. PMID: 32919509 No abstract available.
Progression-free survival in the ICON8 trial.
Ludmir EB, McCaw ZR, Fuller CD, Wei LJ. Ludmir EB, et al. Lancet. 2020 Sep 12;396(10253):756. doi: 10.1016/S0140-6736(20)31175-2. Lancet. 2020. PMID: 32919510 No abstract available.